D N Fish

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Stability of sumatriptan succinate in extemporaneously prepared oral liquids
    D N Fish
    Department of Pharmacy Practice, University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Health Syst Pharm 54:1619-22. 1997
  2. ncbi Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'
    Douglas N Fish
    University of Colorado Health Sciences Center, School of Pharmacy, Campus Box C 238 4200 East Ninth Avenue, Denver, CO 80262, USA
    Expert Rev Anti Infect Ther 1:371-87. 2003
  3. ncbi Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients
    Douglas N Fish
    University of Colorado Health Sciences Center, Department of Clinical Pharmacy, School of Pharmacy, Campus Box C 238, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Antimicrob Agents Chemother 49:2421-8. 2005
  4. ncbi Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit
    Douglas N Fish
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238, Denver, CO, USA
    Int J Antimicrob Agents 29:715-23. 2007
  5. ncbi Optimal antimicrobial therapy for sepsis
    Douglas N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238, Denver, CO 80262, USA
    Am J Health Syst Pharm 59:S13-9. 2002
  6. ncbi Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Antimicrob Agents Chemother 43:1277-80. 1999
  7. ncbi Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Health Syst Pharm 56:1957-60. 1999
  8. ncbi Management of protease inhibitor-associated diarrhea
    D S Sherman
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Infect Dis 30:908-14. 2000
  9. ncbi Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients
    R S Malone
    Department of Pharmacy Practice and Science, School of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA
    Antimicrob Agents Chemother 45:2949-54. 2001
  10. ncbi Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital
    R Jung
    Antimicrobial Research Laboratory, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238 Denver, CO 80262, USA
    J Hosp Infect 57:105-11. 2004

Detail Information

Publications32

  1. ncbi Stability of sumatriptan succinate in extemporaneously prepared oral liquids
    D N Fish
    Department of Pharmacy Practice, University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Health Syst Pharm 54:1619-22. 1997
    ..Sumatriptan 5 mg/mL (as the succinate salt) in three oral suspensions was stable for up to 21 days when stored without light at 4 degrees C...
  2. ncbi Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'
    Douglas N Fish
    University of Colorado Health Sciences Center, School of Pharmacy, Campus Box C 238 4200 East Ninth Avenue, Denver, CO 80262, USA
    Expert Rev Anti Infect Ther 1:371-87. 2003
    ....
  3. ncbi Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients
    Douglas N Fish
    University of Colorado Health Sciences Center, Department of Clinical Pharmacy, School of Pharmacy, Campus Box C 238, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Antimicrob Agents Chemother 49:2421-8. 2005
    ..Higher doses should only be used after consideration of potential central nervous system toxicities or other risks of therapy in these severely ill patients...
  4. ncbi Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit
    Douglas N Fish
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238, Denver, CO, USA
    Int J Antimicrob Agents 29:715-23. 2007
    ..5 microg/mL) associated with community-acquired infections in severely ill ICU patients; less susceptible pathogens (MIC>or=1 microg/mL) do not appear to be optimally treated with currently approved doses...
  5. ncbi Optimal antimicrobial therapy for sepsis
    Douglas N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238, Denver, CO 80262, USA
    Am J Health Syst Pharm 59:S13-9. 2002
    ..The role of monotherapy versus combination therapy is controversial. Routine use of vancomycin and antifungal therapy as part of initial regimens should be discouraged but may be justified in specific circumstances...
  6. ncbi Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Antimicrob Agents Chemother 43:1277-80. 1999
    ..Minimal intrapatient variability of pharmacokinetic parameters was observed in these seriously ill patients...
  7. ncbi Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Health Syst Pharm 56:1957-60. 1999
    ..All the liquids were free of microbial growth for at least 28 days...
  8. ncbi Management of protease inhibitor-associated diarrhea
    D S Sherman
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Infect Dis 30:908-14. 2000
    ..Management of diarrhea is crucial to improving QOL, controlling weight loss, and enhancing overall efficacy of antiretroviral therapy...
  9. ncbi Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients
    R S Malone
    Department of Pharmacy Practice and Science, School of Pharmacy, University of Arizona Health Sciences Center, Tucson, AZ, USA
    Antimicrob Agents Chemother 45:2949-54. 2001
    ..The results of this study suggest that doses of levofloxacin of 250 mg/day and ciprofloxacin of 400 mg/day are sufficient to maintain effective drug concentrations in the plasma of patients undergoing CVVH or CVVHDF...
  10. ncbi Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital
    R Jung
    Antimicrobial Research Laboratory, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Campus Box C 238 Denver, CO 80262, USA
    J Hosp Infect 57:105-11. 2004
    ..On-going surveillance within individual institutions is critical for the selection of appropriate empiric antimicrobial therapy...
  11. ncbi Gatifloxacin, an advanced 8-methoxy fluoroquinolone
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 21:35-59. 2001
    ..Gatifloxacin should prove to be a safe and effective agent for a wide variety of infections...
  12. ncbi Use of enteral nutrition for stress ulcer prophylaxis
    R MacLaren
    School of Pharmacy, C238, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262 0001, USA
    Ann Pharmacother 35:1614-23. 2001
    ..To review the controversies involving the use of enteral nutrition support for stress ulcer prophylaxis and formulate recommendations...
  13. ncbi Fluoroquinolone adverse effects and drug interactions
    D N Fish
    Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 21:253S-272S. 2001
    ....
  14. ncbi Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition
    James Landzinski
    Department of Pharmacy, Georgetown University Hospital, Washington, DC, USA
    JPEN J Parenter Enteral Nutr 32:45-50. 2008
    ..This study evaluated gastric emptying in patients with limited GRV (tolerant group) vs volumes > or =150 mL (intolerant group) and whether prokinetic therapy improves gastric motility in intolerant patients...
  15. ncbi Antimicrobial resistance: factors and outcomes
    Douglas N Fish
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Campus Box C-238, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Crit Care Clin 22:291-311, vii. 2006
    ..Combinations of various approaches may offer the best potential for effectively intervening in and reducing the spread of resistant pathogens in critically ill patients...
  16. ncbi Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction
    Tyree H Kiser
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 26:452-60. 2006
    ..To evaluate the safety, effectiveness, and dosing of bivalirudin for treatment of heparin-induced thrombocytopenia (HIT) in critically ill patients with hepatic and/or renal dysfunction...
  17. ncbi Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia
    Tyree H Kiser
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 25:1736-45. 2005
    ..Platelet-aggregation tests were least useful for evaluating HIT. Appropriate diagnostic strategies should be used to avoid unnecessary drug use...
  18. ncbi Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury
    Tyree H Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, 80262, USA
    Antimicrob Agents Chemother 50:1937-45. 2006
    ..Alternative antibiotics or treatment strategies should be considered for infections due to these pathogens...
  19. ncbi Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients
    Robert MacLaren
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    JPEN J Parenter Enteral Nutr 32:412-9. 2008
    ..The purpose of this study is to evaluate erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric enteral nutrition (EN)...
  20. ncbi Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit
    Jill A Rebuck
    Department of Pharmacotherapy, Fletcher Allen Health Care, University of Vermont, Burlington, USA
    Pharmacotherapy 22:1216-25. 2002
    ..Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin...
  21. ncbi Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates
    Rose Jung
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Antimicrob Agents Chemother 48:1055-7. 2004
    ..Combinations including moxifloxacin demonstrated enhanced bactericidal activity compared with that of either agent tested alone...
  22. ncbi Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs
    Douglas N Fish
    University of Colorado Health Sciences Center, Antimicrobial Research Laboratory, Department of Pharmacy Practice, 4200 E. 9th Ave, Box C238, Denver, CO 80262, USA
    J Antimicrob Chemother 50:1045-9. 2002
    ..There were no differences noted between different cephalosporin and fluoroquinolone combinations. Concentrations used in this study are clinically achievable with recommended regimens in most cases...
  23. ncbi Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated)
    Maria I Rudis
    Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California 90033, USA
    Pharmacotherapy 22:182S-195S. 2002
    ..Drotrecogin alfa (activated) is an important advancement in the treatment of adult patients with severe sepsis...
  24. ncbi Acyclovir concentrations in human breast milk after valaciclovir administration
    Jeanne S Sheffield
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, 75390 9032, USA
    Am J Obstet Gynecol 186:100-2. 2002
    ..The purpose of this study was to determine the valaciclovir and acyclovir pharmacokinetic profiles in serum and breast milk after valaciclovir administration to women after delivery...
  25. ncbi Enteral glutamine supplementation in critically ill patients with burn injuries: a retrospective case-control evaluation
    Paul Juang
    Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, Missouri 63110 1088, USA
    Pharmacotherapy 27:11-9. 2007
    ....
  26. ncbi Assessing renal function in cirrhotic patients: problems and pitfalls
    Deb S Sherman
    Department of Pharmacy, University of Colorado Hospital, Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, CO, USA
    Am J Kidney Dis 41:269-78. 2003
    ....
  27. ncbi Bronchoscopic sampling of drug concentrations: penetration to tissue is the issue
    Douglas N Fish
    Am J Respir Crit Care Med 168:1263-5. 2003
  28. ncbi Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options
    Marilee D Obritsch
    Department of Clinical and Administrative Services, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Pharmacotherapy 25:1353-64. 2005
    ....
  29. ncbi Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study
    Tyree H Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, CO, USA
    Nephrol Dial Transplant 20:1813-20. 2005
    ..No adverse effects related to AVP therapy were observed. CONCLUSION: When compared with OCT, HRS patients treated with AVP had significantly higher recovery rates, improved survival and were more likely to receive a liver transplant...
  30. ncbi Telithromycin: do we really need this antimicrobial?
    Douglas N Fish
    Am J Health Syst Pharm 62:901. 2005
  31. ncbi National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002
    Marilee D Obritsch
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Antimicrob Agents Chemother 48:4606-10. 2004
    ..Ongoing surveillance studies are crucial in monitoring antimicrobial susceptibility patterns and selecting empirical treatment regimens...
  32. ncbi Effects of continuous vasopressin infusion in patients with septic shock
    Marilee D Obritsch
    University of Colorado Hospital, Denver, CO 80262, USA
    Ann Pharmacother 38:1117-22. 2004
    ..In the meantime, vasopressin infusion at <or=0.03 units/min should be considered only if response to 1 or 2 catecholamine vasopressors is inadequate or as a method to reduce the dose of these therapies...